stockrowErasca, Inc.
ERAS Healthcare Biotechnology
- EPS
- −16.7%
- Free cash flow
- −4.67%
Quarter to June 2026, against a year earlier
Follow ERAS
Alert me
Erasca, Inc. (ERAS) Return on equity
Erasca, Inc.'s return on equity over the twelve months to 30 June 2026 was −78.3%, down 45.0 percentage points from fiscal 2025 (−33.3%). Over the past ten years it has ranged from −71.7% (fiscal 2021) to 159.4% (fiscal 2020); the current reading is higher than 71% of that period. That is below the Biotechnology industry median of −52.0% and below the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −33.3% | 10.41 |
| FY2024 | −43.7% | (9.35) |
| FY2023 | −34.3% | 21.59 |
| FY2022 | −55.9% | 15.76 |
| FY2021 | −71.7% | (231.04) |
| FY2020 | 159.4% | 140.49 |
| FY2019 | 18.9% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | 92.2% |
| MANE Veradermics Incorporated compare | 0.00% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −8.08% |
| DNTH Dianthus Therapeutics, Inc. compare | −22.6% |
| CRSP CRISPR Therapeutics AG compare | −25.6% |
| DFTX Definium Therapeutics, Inc. compare | −64.1% |
| ERAS Erasca, Inc. | −78.3% |
| COGT Cogent Biosciences, Inc. compare | −146.6% |
| TVTX Travere Therapeutics, Inc. compare | −252.8% |
| Biotechnology industry median | −52.0% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)